6 recruiting, 1 active not recruiting, 1 not yet recruiting. 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Recruiting 6, Active not recruiting 1, Not yet recruiting 1 |
Follow ctDNA: new trials by email Literature Review of ctDNA trials Research Report on ctDNA
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Circulating Tumor DNA Methylation-Guided Adjuvant Therapy Decision-Making in Patients With Resectable Colorectal Cancer Liver Metastases After Resection Circulating Tumor DNA Methylation Testing, Conventional Postoperative Treatment Strategy - Colorectal Cancer Liver Metastases (CRLM), ctDNA | Phase 2 | Recruiting | Fudan University | 220 | 2026-11-01 | 2026-11-04 |
| Dynamic ctDNA-Guided Adjuvant Therapy in cStage III and IVA Gastric or Gastroesophageal Junction Adenocarcinoma HLX10, SOX Chemotherapy - ctDNA, Gastric Cancer | Phase 2 | Not yet recruiting | Fudan University | 32 | 2026-04-01 | 2026-04-02 |
| ctDNA-guided Treatment Decision-making ADC, Ivonescimab - Metastatic Breast Cancer ( HER2 Negative), ctDNA | Phase 2 | Recruiting | Fudan University | 122 | 2025-12-24 | 2026-02-06 |
| A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy Tislelizumab, Fruquintinib - Minimal Residual Disease, Adjuvant Chemotherapy | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 15 | 2025-09-18 | 2026-08-12 |
| A Randomized Controlled Trial of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy Decision-Making in High-Risk Stage III (T4N+ or T1-3N2) Colorectal Cancer FOLFOX, Folfox plus Bevacizumab - ctDNA, Chemotherapy | Phase 2 | Recruiting | Fudan University | 100 | 2025-04-01 | 2026-05-01 |
| Randomized Study of Plasma ctDNA Methylation to Guide Adjuvant Chemotherapy Decisions in High-Risk T3N0 Colorectal Cancer Capecitabine, FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin) - ctDNA, Chemotherapy | Phase 2 | Recruiting | Fudan University | 340 | 2024-11-01 | 2026-05-01 |
| Randomized Trial of Plasma ctDNA Methylation-Guided Adjuvant Therapy in T4N0 and Low-Risk Stage III Colorectal Cancer CAPEOX regimen - ctDNA, Colorectal Cancer | Phase 2 | Recruiting | Fudan University | 340 | 2024-11-01 | 2026-05-01 |
| Randomized Controlled Study of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy in Stage I/Low-Risk Stage II Colorectal Cancer Capecitabine - ctDNA, Colorectal Cancer (CRC) | Phase 2 | Recruiting | Fudan University | 80 | 2024-11-01 | 2026-05-01 |
Colorectal Neoplasms (5) · Adenocarcinoma (1) · Breast Neoplasms (1) · Neoplasm, Residual (1) · Stomach Neoplasms (1)
Neoplasms (7) · Neoplasms by Site (7) · Digestive System Diseases (6) · Digestive System Neoplasms (6) · Gastrointestinal Diseases (6) · Gastrointestinal Neoplasms (6) · Colonic Diseases (5) · Intestinal Diseases (5) · Intestinal Neoplasms (5) · Rectal Diseases (5) · Breast Diseases (1) · Carcinoma (1) · Neoplasms by Histologic Type (1) · Neoplasms, Glandular and Epithelial (1) · Neoplastic Processes (1)
Capecitabine (2) · Folfox protocol (2) · Bevacizumab (1) · Fluorouracil (1) · HMPL-013 (1) · Leucovorin (1) · Oxaliplatin (1) · XELOX (1) · tislelizumab (1)
Fudan University (7) · M.D. Anderson Cancer Center (1)
China (6) · United States (1)